Haematological toxicities associated with dose-intensive chemotherapy, the role for and use of recombinant growth factors

Annals of Oncology

Volumn 8, Issue SUPPL. 3, 1997, Pages

  Henry, D ^a  

^a Tuttleman Center   (United States)

Author keywords

Anaemia; Epoetin alfa; High dose chemotherapy; Progenitor cell mobilisation; Red blood cell transfusion

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TOXICITY; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CELL MOTILITY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA;

EID: 0030798188     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/8.suppl_3.s7     Document Type: Conference Paper

References (27)

1. Bernstein H, Burnett M, Cairo M. A multicenter observational study of platelet (pit) utilization among recipients of myeloablative therapy and stem cell transplantation (SCT). Proc ASCO 1996; 15: 84 (Abstr).
2. Attkinson K, Norrie S, Chan P et al. Haemopoietic progenitor cell function after HLA-identical sibling bone marrow transplantation: Influence of chronic graft-versus-host disease. Int J Cell Cloning 1986; 4: 203-20.
3. Ma DF, Varga DE, Biggs JC. Haemopoietic reconstitution after allogeneic bone marrow transplantation in man: Recovery of haemopoietic progenitors (CFU-mix, BFU-E and CFU-GM). Br J Haematol 1987; 65: 5-10.
4. Goldwasser E. Erythropoietin and its mode of action. Blood Cells 1984; 4: 147-62.
5. Dessypris EN, Garber SE, Krantz SB, Stone WJ. Effects of recombinant erythropoietin on the concentration and cycling status of human marrow haemopoietic progenitor cells in vivo. Blood 1988; 72: 2060-2.
6. Dessypris EN, Krantz SB. Effects of pure erythropoietin on DNA-synthesis by human marrow day 15 erythroid burst forming units in short term liquid culture. Br J Haematol 1984; 56: 295-306.
7. Schapira L, Antin JH, Ransil BJ et al. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. J Am Soc Haematol 1990; 76 (11): 2354-9.
8. Ireland RM, Atkinson K, Concannon A et al. Serum erythropoietin changes in autologous and allogeneic bone marrow transplant patients. Br J Haematol 1990; 76: 128-34.
9. Krantz SB. Erythropoietin. Blood 1991; 77: 419.
10. Jacobs K, Shoemaker C, Rudersdorf R et al. Isolation and characterisation of genomic and cDNA clones in human erythropoietin. Nature 1985; 313: 806.
11. Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 82: 7580.
12. Steegman JL, López J, Otero MJ et al. Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: Results of a prospective controlled randomised trial. Bone Marrow Transplant 1992; 10: 541-6.
13. Klaesson S, Ringdén O, Ljungman P et al. Reduced blood transfusion requirements after allogeneic bone marrow transplantation: Results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 1994; 13: 397-402.
14. Locatelli F, Zecca M, Pedrazzoli P et al. Use of recombinant human erythropoietin after bone marrow transplantation in paediatric patients with acute leukemia: Effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 1994; 13: 403-10.
15. Ayash LJ, Elias A, Hunt M et al. Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. Br J Haematol 1994; 87: 153-61.
16. Link H, Fauser A, Hubner G et al. Recombinant human erythropoietin after bone marrow transplantation: A prospective placebo controlled trial in Europe. Blood 1993; 82: 284a (Abstr).
17. Peliska J, Miller C, Bishop M et al. Recombinant human erythropoietin therapy for patients with decreased erythropoietin after bone marrow transplantation. Blood 1993; 83: 763a (Abstr).
18. Dessypris EN, Gleaton JH, Armstrong OL. Effect of recombinant erythropoietin on human marrow megakaryocyte colony formation in vitro. Br J Haematol 1987; 65: 265-9.
19. Hino M, Miyazono K, Urabe A, Takaku F. Effects of recombinant human erythropoietin on haemopoietic progenitors of chronic haemodialysis patients in vitro and in vivo. Int J Cell Cloning 1989; 7: 257-62.
20. Ishibashi T, Koziol JA, Burstein SA. Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J Clin Invest 1987; 79: 286-9.
21. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990; 84: 6934-8.
22. Caracciolo D, Clark S, Rovera G. Differential activity of recombinant colony-stimulating factors in supporting proliferation of human peripheral blood and bone marrow myeloid progenitors in culture. Br J Haematol 1989; 72: 306-11.
23. Geissler K, Valent P, Mayer P et al. Recombinant human interleukin-3 expands the pool of circulating hematopoietic progenitor cells in primates synergism with recombinant human granulocyte/macrophage colony-stimulating factor. Blood 1990; 75: 2305-10.
24. Ganser A, Bergmann M, Volkers B et al. In vivo effects of recombinant human erythropoietin on circulating human hemopoietic progenitor cells. Exp Haematol 1989; 17: 433-5.
25. Oliveri A, Offidani M, Cantori I et al. Addition of erythropoietin to granulocyte colony-stimulating factor after priming chemotherapy enhances hemopoietic progenitor mobilization. Bone Marrow Transplant 1995; 15: 765-70.
26. Del Mastro L, Venturini M, Garrone O et al. Erythropoietin in the prevention of chemotherapy-induced anemia: Results from a randomized trial in early breast cancer patients [Abstr no. 697]. In Perry MC (ed): Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology, May 20-23 1995, Los Angeles. Toronto: WB Saunders 1995; 256.
27. Venturini M, Del Mastro L,Testore Fet al. Erythropoietin (EPO) and G-CSF allow intensification and acceleration of CEF regimen [Abstr no. 696]. In Perry MC (ed): Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology, May 20-23 1995, Los Angeles. Toronto: WB Saunders 1995; 256.